RSV Prophylaxis with Nirsevimab: A Notable Reduction in Infant Illness
The respiratory syncytial virus (RSV) traditionally causes a surge in respiratory illness, especially between October and March, frequently enough overwhelming pediatric care facilities. Historically, preventative measures were limited to passive immunization for infants with pre-existing health conditions. However, recent recommendations from the Standing Vaccination Commission (Stiko) now advocate for worldwide prophylaxis with nirsevimab, a monoclonal antibody, for all newborns.
Approved for use in the EU as October 2022, nirsevimab (Beyfortus®) provides protection during an infant’s first RSV season, irrespective of prior health status. The antibody works by preventing the fusion of infected cells with healthy cells, effectively halting the virus’s spread. A single intramuscular injection offers protection for the entire RSV season.
Beginning in 2024, Stiko broadened its suggestion to include routine nirsevimab vaccination for all newborns, or during their first RSV season, irrespective of risk factors. This expansion also includes a single dose recommendation for adults over 75 and those 60 and older with underlying health conditions, aiming to minimize severe RSV-related respiratory disease, hospitalization, and mortality.
RSV is a common RNA virus transmitted through respiratory droplets, posing a significant threat to infants, young children, and older adults, with peak incidence during winter months. Globally, a substantial number of infants experience RSV infection in their first year of life, often requiring hospitalization. In Germany alone, approximately 25,000 infants are affected annually. Importantly, infection does not confer long-lasting immunity, meaning most children will experience at least one RSV infection by age two. premature infants, newborns, and those with underlying medical conditions are particularly vulnerable, as are adults with cardiac, pulmonary, or immune deficiencies.
Prior to the availability of nirsevimab, treatment focused solely on symptom management – ensuring adequate hydration and maintaining clear airways. While complete prevention of infection remains challenging, good hygiene practices and prompt diagnosis can help mitigate severe illness.
Recent evaluation by the Federal Joint Committee (G-BA) has confirmed a “considerable additional benefit” of nirsevimab in preventing RSV infection in infants under one year of age. Clinical trials comparing nirsevimab to placebo and no therapy demonstrated a significant reduction in lower respiratory tract RSV infections, particularly severe cases.
Data from the 2024/25 RSV season reveals a substantial impact: cases among newborns and infants decreased by 54% compared to the 2023/24 season, falling from 2,291 to 1,045 illnesses per 100,000 infants.Correspondingly, hospitalizations due to RSV declined by 55%, highlighting the effectiveness of nirsevimab prophylaxis.
Heike Lachnit
Sources: (As per original article)
